Stocktoria

Estrella Immunopharma, Inc. ESLA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-19

Estrella Immunopharma, Inc. statistics & valuation

Market cap$42.3M

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202120222022202320242025
Operating margin (%)
202120222022202320242025
Return on equity (%)
-171.10% 202120222022202320242025
Shares outstanding
1.4M 1.4M 1.4M 978243 36.6M 36.8M 202120222022202320242025
Net debt ($)
202120222022202320242025
Share buybacks ($)
202120222022202320242025
Return on assets (%)
-0.50% -10.20% -367.00% -164.20% -411.20% 202120222022202320242025
Free cash flow margin (%)
202120222022202320242025
Debt / equity (×)
202120222022202320242025
EPS ($)
-$36.35 -$0.27 -$0.35 202120222022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2022FY2021
Return on assets-411.2%-164.2%-367.0%-10.2%—-0.5%
Return on equity126.0%-171.1%94.7%15.4%—24.6%
Current ratio0.1224.650.280.050.838.42

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.